MetLife Investment Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

MetLife Investment Management’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,035	Closed	-$160K	–	2338
2020 Q3	$160K	Hold	3,035	–	–	﹤0.01%	1996
2020 Q2	$186K	Hold	3,035	–	–	﹤0.01%	1954
2020 Q1	$172K	Hold	3,035	–	–	﹤0.01%	1783
2019 Q4	$173K	Hold	3,035	–	–	﹤0.01%	2054
2019 Q3	$162K	Hold	3,035	–	–	﹤0.01%	2063
2019 Q2	$181K	Hold	3,035	–	–	﹤0.01%	2086
2019 Q1	$189K	Hold	3,035	–	–	﹤0.01%	2007
2018 Q4	$184K	Hold	3,035	–	–	﹤0.01%	1958
2018 Q3	$178K	Buy	+3,035	New	+$155K	﹤0.01%	2150
2018 Q1	–	Sell	-3,039	Closed	-$132K	–	2229
2017 Q4	$132K	Buy	+3,039	New	+$137K	﹤0.01%	2138

Other funds holding BSTC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

MetLife Investment Management's BSTC Position: Q4 2020 in Review

MetLife Investment Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 3,035 shares — an estimated $160K sold.

MetLife Investment Management first reported a position in BSTC in Q4 2017 and held it in 10 quarters. The position peaked at $189K in Q1 2019. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.

MetLife Investment Management reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
MetLife Investment Management sold 3,035 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $160K.
MetLife Investment Management first reported a position in BioSpecifics Technologies Corp. in Q4 2017 and held it in 10 quarters.
MetLife Investment Management's BioSpecifics Technologies Corp. position peaked at $189K in Q1 2019.
1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.

Based on MetLife Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.